Mackay Sean 4

What Happened

• Sean Mackay, SVP & Chief Business Officer of Standard BioTools (LAB), was granted 500,000 restricted stock units (RSUs) on 2026-06-20 (transaction coded as an award/acquisition). The filing reports an acquisition price of $0.00 (no cash paid). Each RSU represents the right to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-06-20; SEC filing date: 2026-06-23 (no late filing indicated in the report).
• Award: 500,000 RSUs, reported at $0.00 per unit (code A — award/grant).
• Vesting: 40% (200,000 RSUs) vest on June 20, 2027; remaining 60% (300,000 RSUs) vest on June 20, 2028, subject to continued service (per footnote F1).
• Shares owned after the transaction: not specified in the provided filing summary.
• Footnote: Each RSU converts to one share upon vesting; vesting is service-based.

Context

• RSUs are a form of equity compensation and do not involve an open‑market purchase or immediate share issuance; shares are issued only when RSUs vest. Such awards are commonly used for retention and compensation and should not be read as a direct buy/sell signal.